Pfizer Challenge To Lyrica Abuse Liability Assessment Delayed Approval
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Pfizer removed the final hurdle to approval of Lyrica (pregabalin) when it relented in its opposition to FDA's assessment of the potential for abuse of the drug, agency review documents show